Abstract
RAS is a molecular switch that regulates a large number of pathways through interactions with many effector proteins. Most RAS/effector complexes are short-lived, demonstrating fast association and fast dissociation rate and Kds ranging from 10-8–10-5 M, compatible with the signaling function of these interactions in the cell. RAS effectors share little sequence homology but all contain an RAS binding domain that exhibits ubiquitin fold. All effectors bind to the same epitope on RAS by forming an intermolecular beta sheet and creating a number of favorable hydrogen bonds and salt bridges across the binding interface. Several hot-spots on both RAS and effector molecules constitute a general recognition mode. RAS/effector interactions occur only when RAS is found in the active, GTP-bound state, and are disrupted upon GTP hydrolysis, most probably due to increased flexibility of the RAS molecule. Recent NMR studies demonstrate how in the presence of multiple binding partners, RAS prefers certain effectors to others. The hierarchy of these interactions could be altered for RAS oncogenic mutants, thus perturbing the network of the downstream signaling. Insights obtained through biophysical and structural studies of effectors interacting with RAS and its mutants establish the basic principles that could be used for designing drugs in RAS-associated diseases.
Keywords: Binding affinity, complex structure, intermolecular interactions, protein-protein interactions.
Mini-Reviews in Medicinal Chemistry
Title:RAS/Effector Interactions from Structural and Biophysical Perspective
Volume: 16 Issue: 5
Author(s): Ariel Erijman and Julia M. Shifman
Affiliation:
Keywords: Binding affinity, complex structure, intermolecular interactions, protein-protein interactions.
Abstract: RAS is a molecular switch that regulates a large number of pathways through interactions with many effector proteins. Most RAS/effector complexes are short-lived, demonstrating fast association and fast dissociation rate and Kds ranging from 10-8–10-5 M, compatible with the signaling function of these interactions in the cell. RAS effectors share little sequence homology but all contain an RAS binding domain that exhibits ubiquitin fold. All effectors bind to the same epitope on RAS by forming an intermolecular beta sheet and creating a number of favorable hydrogen bonds and salt bridges across the binding interface. Several hot-spots on both RAS and effector molecules constitute a general recognition mode. RAS/effector interactions occur only when RAS is found in the active, GTP-bound state, and are disrupted upon GTP hydrolysis, most probably due to increased flexibility of the RAS molecule. Recent NMR studies demonstrate how in the presence of multiple binding partners, RAS prefers certain effectors to others. The hierarchy of these interactions could be altered for RAS oncogenic mutants, thus perturbing the network of the downstream signaling. Insights obtained through biophysical and structural studies of effectors interacting with RAS and its mutants establish the basic principles that could be used for designing drugs in RAS-associated diseases.
Export Options
About this article
Cite this article as:
Erijman Ariel and Shifman M. Julia, RAS/Effector Interactions from Structural and Biophysical Perspective, Mini-Reviews in Medicinal Chemistry 2016; 16 (5) . https://dx.doi.org/10.2174/1389557515666151001141838
DOI https://dx.doi.org/10.2174/1389557515666151001141838 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
From Endothelial to β Cells: Insights into Pancreatic Islet Microendothelium
Current Diabetes Reviews Advances in Spirocyclic Hybrids: Chemistry and Medicinal Actions
Current Medicinal Chemistry Tankyrase as a Novel Molecular Target in Cancer and Fibrotic Diseases
Current Drug Targets Autophagy and Crohns Disease: At the Crossroads of Infection, Inflammation, Immunity, and Cancer
Current Molecular Medicine Protective Mechanisms of Helminths Against Reactive Oxygen Species are Highly Promising Drug Targets
Current Medicinal Chemistry Alginate Bead-Encapsulated PEDF Induces Ectopic Bone Formation In Vivo in the Absence of Co-Administered Mesenchymal Stem Cells
Current Drug Targets Mouse Models of Autoimmune Uveitis
Current Pharmaceutical Design Approaches for Administering Chemotherapy in the Intensive Care Unit
Current Drug Safety Family-Based Therapy for Adolescent Anorexia: The Nuts and Bolts of Empowering Families to Renourish Their Children
Adolescent Psychiatry New Trends in Biological Activities and Clinical Studies of Quinolinic Analogues: A Review
Current Drug Targets MTHFR Gene Polymorphism and Diabetic Retinopathy
Current Diabetes Reviews Circadian Clock Gene of Grass Carp (Ctenopharyngodon idellus): Genomic Structure and Tissue Expression Pattern of Period1 Gene
Current Bioinformatics Recent Patents in Circulating Cell-Free Tumor DNA as Biomarker in Cancer
Recent Patents on Biomarkers Antagonism by Bioactive Polyphenols Against Inflammation: A Systematic View
Inflammation & Allergy - Drug Targets (Discontinued) Neurodevelopment in Schizophrenia: The Role of the Wnt Pathways
Current Neuropharmacology Review of and Perspectives on the Toxicology of Graphene-based Materials
Current Drug Metabolism The Role of Melatonin in Multiple Sclerosis, Huntington's Disease and Cerebral Ischemia
CNS & Neurological Disorders - Drug Targets Interleukin-24: A Molecule with Potential Anti-Cancer Activity and a Cytokine in Search of a Function
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial [Hot Topic: Angiogenesis in Tumor Growth and Metastasis (Executive Editor: Riichiro Abe)]
Current Pharmaceutical Design The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases
Current Medicinal Chemistry